The Gemini-AALA (Australia, Asia, Latin America, Africa/ Middle East) study evaluated the efficacy and safety of single-pill amlodipine/atorvastatin (Caduet) for the treatment of patients of diverse ethnicity with concomitant hypertension and dyslipidaemia. This was a 14-week, open-label study including patients from 27 ). At week 14, 55.2% of patients reached both blood pressure and lipid goals, 61.3% reached blood pressure goal and 87.1% reached lipid goal (34.0% were at lipid goal at baseline). Mean blood pressure reduction was 20.2/11.4 mm Hg. For patients who were lipid-lowering drug naive at baseline, mean reduction inIntroduction Cardiovascular disease (CVD) is a major cause of morbidity and mortality worldwide, and is a growing burden in lower/middle-income countries. 1, 2 Approximately two-thirds of stroke and half of ischaemic heart disease events worldwide occur as a consequence of elevated blood pressure (BP). 3 In a recent study, Kearney et al. 4 estimated that 26.4% of the adult population worldwide in 2000 had hypertension, and predicted that the number of people with hypertension will increase by approximately 60% by 2025. In this analysis, high rates of hypertension were seen in Latin America and the Caribbean, whereas rates were lower in countries across Asia, the Middle East and Africa. 4 However, the number of people with hypertension was predicted to rise most rapidly in economically developing countries (by approximately 80% by 2025) as compared with economically developed countries (by approximately 24% by 2025). 4 The rising incidence of hypertension in these regions is likely to have a large impact on the global burden of CVD.
Hypertension frequently occurs alongside other cardiovascular (CV) risk factors, in particular dyslipidaemia. [5] [6] [7] Furthermore, the co-occurrence of hypertension and dyslipidaemia has been shown to have a more than additive effect on CV risk. [8] [9] [10] Evidence-based guidelines now recommend the assessment of overall CV risk and aggressive treatment of multiple CV risk factors for the management of CVD. [11] [12] [13] [14] Single-pill combination therapy, aimed at lowering both BP and lipids simultaneously, may be an effective strategy for managing patients' overall CV risk through concomitant treatment with antihypertensive and lipid-lowering therapies. This strategy may have additional benefits such as improved patient adherence and convenience of dosing. 15 A single pill containing the dihydropyridine calcium channel blocker (CCB) amlodipine and the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor atorvastatin is available (in up to 11 different dosages) in many countries for the treatment of patients with hypertension and dyslipidaemia. 16 Both amlodipine and atorvastatin have been shown to be efficacious and safe for lowering BP and lipid levels, respectively, as well as reducing the incidence of CV events. [17] [18] [19] [20] [21] [22] Furthermore, both coadministered amlodipine and atorvastatin, or singlepill amlodipine/atorvastatin, are an effective and safe means of helping patients attain recommended BP and lipid targets. [23] [24] [25] [26] [27] [28] Limited data are currently available concerning the treatment patterns for patients with hypertension and dyslipidaemia in countries across the Middle East, Asia-Pacific, Africa and Latin America; to date, no large-scale clinical trial has been undertaken to study the treatment of more than one CV risk factor in hypertensive patients across these regions. The utility of single-pill amlodipine/atorvastatin has previously been assessed in studies in the United States, Europe and Canada. [24] [25] [26] [27] The Gemini-AALA (Australia, Asia, Latin America, Africa/Middle East) study was designed to complement these trials by assessing the clinical utility of single-pill amlodipine/atorvastatin in patients from the Middle East, Asia-Pacific, Africa and Latin America. The primary objective of the Gemini-AALA study was to assess the efficacy and safety of single-pill amlodipine/atorvastatin in patients of diverse ethnicity with hypertension and dyslipidaemia and to gain clinical experience in these regions of dosing and titrating a single pill containing these two agents.
Materials and methods

Study design
The Gemini-AALA study was a 14-week, real-world, prospective, titration-to-goal, non-comparative, openlabel trial conducted at 123 centres across 27 countries in the Middle East/Africa (Israel, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, South Africa, Tunisia, Turkey and United Arab Emirates), Asia-Pacific (Australia, Hong Kong, India, Indonesia, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan and Thailand) and Latin America (Argentina, Brazil, Chile, Guatemala, Mexico, Peru). Figure 1 illustrates the overall study design. The protocol was approved by the local Independent Ethics Committee at all sites, and the study was conducted in compliance with good clinical practice and International Conference on Harmonization guidelines. All patients had the study explained to them and signed consent forms prior to screening.
Patient population
Patients were aged 18-80 years with a diagnosis of concurrent hypertension and dyslipidaemia. Patients were excluded if their BP was at goal or if they were currently being treated with concomitant amlodipine and atorvastatin therapy, amlodipine 10 mg or other maximum dose CCB, or atorvastatin 80 mg with low-density lipoprotein cholesterol (LDL-C) X2.6 mmol l À1 (X100 mgdl À1 ). Patients receiving lipid-lowering therapy could be at goal for LDL-C at baseline. Other standard exclusion criteria, as described earlier, 24 were applied. Patient's self-reported ethnicity was recorded by the physician on the case report form.
Patients were classified into one of three CV risk categories based on the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) 29 and National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (NCEP ATP III) 11 guidelines for BP and LDL-C levels, respectively, and the presence of other CV risk factors (defined according to NCEP ATP III guidelines 11 ) in addition to hypertension and dyslipidaemia (Table 1) . Goals for BP and LDL-C were also defined by JNC 7 29 and NCEP ATP III 11 guidelines, except for CV risk group III, in which a BP goal of o130/80 mm Hg was used irrespective of diabetes status.
Study and concomitant medications
Single-pill amlodipine/atorvastatin (Caduet; Pfizer Inc, New York, USA) was available in eight different dosage strengths (amlodipine/atorvastatin 5/10, 10/10, 5/20, 10/20, 5/40, 10/40, 5/80, 10/80 mg) that were flexibly titrated throughout the study. At the baseline visit, patients were instructed in the NCEP Step 1 Diet, and initial study medication dose was determined based on BP and LDL-C levels and prior drug therapy. 24 There was no washout of background lipid-lowering or antihypertensive med-ications. Upward and downward titration of study drug was based, at a minimum, on whether patients achieved BP and LDL-C goals ( 
LDL-C inclusion criteria (patients treated with lipid-lowering medication)
Abbreviations: BP, blood pressure; CHD, coronary heart disease; CV, cardiovascular; DBP, diastolic blood pressure; DM, diabetes mellitus; DYS, dyslipidaemia; HDL-C, high-density lipoprotein cholesterol; HTN, hypertension; LDL-C, low-density lipoprotein cholesterol; SBP, systolic blood pressure. 
Efficacy measures
The primary efficacy measure was the percentage of patients achieving both BP and LDL-C goals (Table 1 ) after 14 weeks. Secondary efficacy measures included the following: absolute and percentage change from baseline in BP and lipid levels; BP and LDL-C goal attainment stratified by prior antihypertensive and lipid-lowering medications; and BP and LDL-C goal attainment by country and geographical region.
BP and lipid measurements
At each of two or three screening visits (2-3 weeks prior to study initiation), the average of three BP readings was obtained, and the mean BPs for each screening visit were averaged to determine the baseline BP. BP was recorded at subsequent visits as detailed in Figure 1 . Measurements for BP were taken on the same arm throughout the study using a mercury manometer. Patients were requested to minimize food or caffeine intake, cigarette smoking and exercise within 2 h prior to BP measurement. Blood specimens were drawn at each screening visit for an 8-h fasting serum lipid profile and standard blood testing. Lipids were measured (following an 8-h fasting period) during open-label treatment as detailed in Figure 1 . A single laboratory in each country was chosen as the 'central laboratory' for that country. To standardize lipid measurements, central laboratories were sent a cholesterol standard to measure. If the lipid measurements were not within pre-specified ranges, (i) laboratories agreed to adjust their measurement or reagents, after which they were re-evaluated for standardization; (ii) if laboratories would/could not make appropriate adjustments to their measurements, or could not guarantee the consistent use of reagents, a numerical adjustment algorithm was determined for each laboratory based on results of a control serum sample, and applied to the data to bring all measurements into the specified range. Laboratories for which deviations from the standard measurements could not be adequately corrected were not selected as central laboratories. Identification of laboratories took place prior to the commencement of recruitment.
Calculation of overall CV risk
In a post hoc analysis, Framingham 10-year coronary heart disease (CHD) risk was estimated for patients in CV risk groups I and II (those patients without pre-existing CHD or a risk equivalent), based on age, sex, total cholesterol, high-density lipoprotein cholesterol (HDL-C), BP, diabetes and smoking status (age and smoking were presumed to be constant during the study). 30 
Safety assessments
Details concerning all adverse events (AEs) or serious AEs (observed or reported) were documented at each visit. Untoward, clinically significant changes in physical examination findings and abnormal test results were also recorded as AEs.
Statistical analysis
The study was designed to enrol approximately 2000 patients to estimate with high precision (that is, 95% confidence interval (CI) o5% in width) the proportion of patients treated with amlodipine/ atorvastatin who would achieve both BP and lipid treatment goals (assumed to be 50-60%), allowing for 20% dropout.
All patients who took at least one dose of the study medication and provided any follow-up safety information were included in the safety analysis. Patients with any post-baseline measurements for efficacy were included in the intent-to-treat (ITT) population with the last observation carried forward for analysis. Descriptive statistics and 95% CIs were presented for all efficacy data. Appropriate Statistical Analysis Systems (SAS) procedures were used to generate analysis results.
Results
Of 2585 patients screened, 1649 were included in the safety analysis ( Figure 1 ). Although the target enrolment of 2000 patients was not met, a sufficient number of patients were included in the ITT population (1638 (99.3%) of all treated patients), owing to a low dropout rate.
Patients had a mean age of 59 years, with slightly more females (51.2%) than males. Approximately 51.7% of patients were reported by the patient/ investigator as of Asian ethnicity, 32.9% as white and 0.7% as black. A large proportion of patients reported as of 'other' ethnicity were Latin American ( Table 2) . Across all patient groups, mean baseline BP was 146.6/88.3 mm Hg and mean baseline LDL-C was 3.4 mmol l À1 (130.2 mgdl À1 ) ( Table 2 ). The baseline BP and LDL-C were as follows for each study region: Middle East/Africa, 149.4/88.9 mm Hg and 3.5 mmol l À1 (134.0 mgdl À1 ); Latin America, 147.1/ 90.9 mm Hg and 3.6 mmol l À1 (139.9 mgdl À1 ); and Asia-Pacific, 145.0/87.1 mm Hg and 3.2 mmol l À1 (124.9 mgdl À1 ). The majority of study participants (1508/1649; 91.4%) had at least one CV risk factor (see Table 1 for definitions) in addition to hypertension and dyslipidaemia, and 61.7% (1017/1649) had CHD or a risk equivalent and were included in CV risk group III ( Table 2 ). The mean Framingham 10-year CHD risk among ITT patients without pre-existing CHD or a risk equivalent (that is, CV risk groups I and II) was 13.4% at baseline.
Among ITT patients, 228 (13.9%) had received no previous treatment for either hypertension or dyslipidaemia, over half (51.1%) had received no previous treatment for dyslipidaemia and 306 (18.7%) were naive to antihypertensive medications. The most common antihypertensive and lipid-lowering treatments received before the start of the study were angiotensin-converting enzyme inhibitors (33.6% of patients) and HMG-CoA reductase inhibitors (46.9%), respectively. Overall, 93% of patients reported taking at least one concomitant treatment during the study period. The most common antihypertensive medications taken concomitantly with the study drug were b-blockers (39.7%), angiotensin-converting enzyme inhibitors (33.3%), thiazides and related diuretics (17.8%) and angiotensin II receptor antagonists (12.5%).
Administration and titration of study medications At baseline, 50% of patients were started on the lowest dose of amlodipine 5 mg/atorvastatin 10 mg and 7.4% on amlodipine 10 mg/atorvastatin 10 mg. At the last visit, 31.8% of patients were receiving amlodipine 5 mg/atorvastatin 10 mg, 20.3% were receiving amlodipine 10 mg/atorvastatin 10 mg, 1.8% were receiving the maximum dose of amlodipine 10 mg/atorvastatin 80 mg and less than 4% of patients were on the highest dose of atorvastatin in combination with either amlodipine 5 or 10 mg. At the end of the study, the mean (s.d.) dosage was 7.1 mg (2.5) amlodipine/19.7 mg (15.4) atorvastatin. Mean (s.d.) adherence to the study medication (as measured by tablet count) was 96.2 (12.8)%.
Attainment of both BP and LDL-C goals
More than half (55.2%) of patients reached both their BP and LDL-C targets at the end of week 14 (Figures 2a and 3) . A higher percentage of patients in CV risk groups I and II attained both their BP and LDL-C goals (81.3 and 78.8%, respectively), as compared with CV risk group III (40.3%) (Figure 2a ). When those patients in CV risk group III without diabetes (n ¼ 407) were further analysed using a BP goal of o140/90 mm Hg (as appropriate for JNC 7 criteria, rather than o130/80 mm Hg recommended for patients with diabetes), goal attainment for both BP and LDL-C non-diabetic patients rose to 70.0%. The attainment of both BP and lipid goals for certain subgroups of patients is listed in Table 3 . The proportion of patients attaining both goals in each country and by region is illustrated in Figure 4 .
Attainment of BP goals
At week 14, 61.3% of patients had reached their BP goal (Figure 2b ). However, when goal attainment for patients in CV risk group III who did not have diabetes was considered using a BP goal of o140/ 90 mm Hg (as appropriate for JNC 7 criteria), 87.5% of these patients achieved this BP level. A dose titration analysis showed that over the study period, the amlodipine dose was not up-titrated from 5 to 10 mg for a number of patients who did not achieve their BP goal. At weeks 6, 10 and 12, 17.9, 16.0 and 13.9% of patients, respectively, were not at goal but were maintained on amlodipine 5 mg.
Attainment of LDL-C goals
Among all patients, 87.1% reached their LDL-C goals (compared with 34.0% at baseline) (Figure 2c ). (Table 4) . Among patients naive for lipid-lowering therapy at baseline, the mean percentage reduction in LDL-C was 41.0% (absolute reduction of 1.7 mmol l À1 (64.5 mgdl À1 )).
Patients receiving lowest dose atorvastatin
An additional analysis revealed that among patients initiated on the lowest dose of atorvastatin, including those who were subsequently up-titrated during the study (n ¼ 941 in total), the mean percentage reduction from baseline in LDL-C, for the last measurement prior to up-titration (or final observation for patients who remained on this dose), was 28.5% (absolute reduction of 1.1 mmol l À1 (43.8 mgdl À1 )). The mean reduction in BP for this population was 19.9/11.2 mm Hg. Among these patients, the mean percentage reduction in LDL-C for those who remained on 10 mg atorvastatin throughout the study (n ¼ 805) was 29.0% (1.1 mmol l À1 (44.0 mgdl À1 )) at last observation, as compared with 25.5% (1.1 mmol l À1 (42.4 mgdl À1 )) for patients who were up-titrated (at the last visit before up-titration; n ¼ 136). Corresponding reductions in BP for these patients were 20.6/11.7 and 15.6/8.7 mm Hg, respectively.
Effects on overall CHD risk Among patients from CV risk groups I and II, mean 10-year Framingham CHD risk was reduced by approximately half (mean percentage decrease, 49.6%) from 13.4% at baseline to 6.2% at last observation (mean decrease 7.2% (95% CI: 6.7, 7.6), Po0.001). For patients who had received no previous antihypertensive or lipid-lowering thera- An additional 136 patients initiated on this dose were later up-titrated.
The Gemini-AALA study S Erdine et al pies at baseline, mean Framingham CHD risk was reduced by over half (mean percentage decrease 56.0%) from 14.6 to 6.2% (mean decrease 8.4% (95% CI: 7.5, 9.3), Po0.001). Figure 5 illustrates the change in Framingham risk for each region and country participating in the study.
Safety and tolerability
Overall, 141 (8.6%) patients discontinued for any reason. AEs led to the discontinuation of 77 (4.7%) patients; of these, 60 (3.6%) discontinued due to treatment-related AEs. The most common reason for discontinuation was peripheral oedema, leading to the discontinuation of 18 (1.1%) patients. A total of 725 (44.0%) patients had at least one treatment-emergent AE (1290 AEs were reported overall). The most common AEs were peripheral oedema (9.8%), respiratory tract infection (5.0%), headache (3.3%), dizziness (3.1%), arthralgia (1.7%), asthenia (1.7%), palpitation (1.5%) and myalgia (1.5%). Of 161 patients reporting peripheral oedema, five (3.1%) were classified as having a severe AE. Most AEs were mild to moderate in severity; 39 were classed as severe. All cases of myalgia were either mild or moderate in severity and two resulted in discontinuations. Seven patients experienced severe CV-related AEs. A total of 363 (22.0%) patients had at least one AE judged by the investigator to be most likely due to the study treatment or unknown cause (520 treatment-related AEs were reported overall). Only peripheral oedema occurred in more than 2% of patients (8.6%). By region, more patients in Latin America (35.9%) had treatment-related AEs than in the Middle East/Africa (16.4%) or Asia-Pacific (20.1%), and peripheral oedema (treatment-related) was reported in 20.9% of Latin American patients as compared with 6.1 and 5.6%, in the Middle East/ Africa and Asia-Pacific, respectively.
A total of 32 (1.9%) patients had at least one serious AE, only one of which was considered by the investigator to be related to study medication. This patient had elevated levels (43 Â upper limit of The Gemini-AALA study S Erdine et al normal) of alanine transaminase, g-glutamyl transferase and alkaline phosphatase, which returned to normal levels at follow-up (with the exception of the g-glutamyl transferase level). Two patients died of carcinoma, one during the study and one within 30 days of the last dose; neither death was considered to be related to the study drug.
Discussion
The Gemini-AALA study was the first large-scale clinical trial in patients from diverse ethnic groups in countries across the Middle East/Africa, Asia-Pacific and Latin America, which specifically investigated the use of a single pill for the concomitant treatment of more than one CV risk factor. These results demonstrate that treatment with single-pill amlodipine/atorvastatin, either alone, or in addition to existing antihypertensive agents, is an effective and safe treatment that helps patients from diverse ethnic backgrounds to reduce their total CHD risk by lowering their BP and lipids towards recommended therapeutic goals.
Overall, 55.2% of patients achieved both goals for BP and LDL-C. It can be noted that goal attainment was comparable between patients from the Middle East/Africa, Asia-Pacific and Latin America. Levels of goal attainment were also comparable with those achieved in the US Gemini study (57.7%, using JNC 6 BP goals 31 ), 24 the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid Endpoints (CAPABLE) study, which evaluated single-pill amlodipine/atorvastatin in African-American patients (48.3%, using JNC 7 BP goals 29 ) 27 and the Jewel programme in Canadian and European patients (55.5%, using country-specific goals). 25, 26 Together, the results of these studies indicate that single-pill amlodipine/atorvastatin therapy aids BP and LDL-C goal attainment among patients from a wide range of countries and ethnic backgrounds.
For the Gemini-AALA study, we elected to base treatment goals on JNC 7 29 and NCEP ATP III 11 guidelines, irrespective of the country in which patients were recruited, to allow for the collation of goal attainment data for the overall study population and direct comparisons between different countries and regions. Although international 32 and European 12-14 guidelines recommend similar BP , multiply by 38.67 for LDL-C, HDL-C and total cholesterol; multiply by 88.57 for triglycerides. *Po0.05; **Po0.001; no adjustments were made for multiple testing.
The Gemini-AALA study S Erdine et al target levels to those used in the Gemini-AALA study, the 2007 European Society of Cardiology guidelines for CVD prevention recommended LDL-C goals slightly lower than in this study (o3.0 mmol l
À1
(115 mgdl À1 ) among the general population of patients with dyslipidaemia, and o2.5 mmol l À1 (100 mgdl À1 ) for those with diabetes/ atherosclerotic CVD with an optional goal of o2.0 mmol l À1 (80 mgdl À1 ) if feasible). 14 However, the impact of different guideline recommendations on the reductions in BP and LDL-C achieved with amlodipine/atorvastatin appears to be minimal, with comparable results between Gemini-AALA and the Jewel 1/2 studies, which used countryspecific targets for the United Kingdom, Canada and Europe. 25, 26 Mean BP was lowered by 20.2/ 11.4 mm Hg in the Gemini-AALA study as compared with 20.4/10.7 mm Hg in Jewel 1 (United Kingdom/ Canada) and 21.8/12.6 mm Hg in Jewel 2 (Europe) studies. 25 The mean reduction in LDL-C was 1.1 mmol l À1 (43.7 mgdl À1 ) for the Gemini-AALA study, 0.90 mmol l À1 (34.8 mgdl À1 ) for the Jewel 1 study and 1.1 mmol l À1 (42.2 mgdl À1 ) for the Jewel 2 study. 25 Changes in BP and LDL-C were also similar in the US Gemini study in which BP was reduced by 17.1/9.6 mm Hg and LDL-C by approximately 1.3 mmol l À1 (50.0 mgdl À1 ; patients with uncontrolled LDL-C at baseline only). 24 Within the Gemini-AALA study, single-pill amlodipine/atorvastatin was effective in lowering BP and LDL-C in patients at differing levels of CV risk, although as expected, a smaller percentage of patients in CV risk group III (40.3%) were controlled than in groups I and II (81.3 and 78.8%, respectively), in part, due to the more aggressive goals for group III. Furthermore, goal attainment was 50.1% even among patients already taking both antihypertensive and lipid-lowering medications at baseline, whereas almost two-thirds (62.7%) of patients naive to both antihypertensive and lipid-lowering therapies achieved both goals.
The achievement of BP and LDL-C targets may have been higher if more patients had been titrated to the higher doses of the single pill. At the last visit, only 1.8% of patients were receiving the highest dose of 10 mg amlodipine/80 mg atorvastatin, and the mean dose at the end of the study was only 7.1 mg amlodipine/19.7 mg atorvastatin (slightly Figure 5 Framingham 10-year risk at baseline and at last observation by country. ITT, intent-to-treat; CV, cardiovascular; UAE, United Arab Emirates.
10-year Framingham risk
The Gemini-AALA study S Erdine et al lower than mean dose in the US Gemini study of 7.1 mg amlodipine/26.2 mg atorvastatin 24 ). An analysis of the level of titration revealed that physicians did not consistently up-titrate the dose of amlodipine or atorvastatin for patients who were not at goal for BP or LDL-C, respectively. Although this analysis did not take into account any potential reasons for physicians' decisions not to up-titrate (for example, possible AEs), this suggests that there may be reluctance among physicians to up-titrate patients to meet therapeutic goals even in a clinical trial setting, despite studies indicating that atorvastatin 80 mg is not associated with an appreciably higher incidence of AEs than lower doses. 28, 33 In comparison with the United States and Europe, 5, [34] [35] [36] little data are available regarding the treatment of patients with hypertension and other CV risk factors for countries across the Middle East/Africa, Asia-Pacific and Latin America. However, published data indicate that the prevalence of patients with multiple CV risk factors is high and that there is a need for improved CV risk factor management in these populations. [37] [38] [39] [40] In addition, although the precise effect of risk factors on CVD events may vary among patients from different ethnic backgrounds, or according to regional lifestyle differences, major risk factors such as hypertension and dyslipidaemia are consistently associated with increased CV risk worldwide. 41, 42 In the recent Paroi artérielle et Risque Cardiovasculaire (PARC)-AALA study, among patients with uncontrolled hypertension (defined as BPX140/ 90 mm Hg) and uncontrolled hypercholesterolaemia (total cholesterol X5.2 mmol l À1 (200 mgdl À1 )) in Asia, Africa/Middle East and Latin America, approximately 39-51% were receiving antihypertensive treatment and only 6-18% were receiving lipid-lowering therapy. 40 Higher percentages of patients in the Gemini-AALA study were receiving prior medications (potentially due to the differing entry criteria for the two studies regarding diagnosis/control of hypertension and dyslipidaemia), even so, over half (51.2%) had received no treatment for dyslipidaemia prior to the study, 18.8% had received no antihypertensive treatment and 14.1% no treatment for either condition; a slightly greater percentage than in the US-based Gemini study in which 12.7% of patients were naive to both antihypertensive and lipid-lowering drugs. 24 Poor treatment rates and low goal attainment may be due, in part, to a lack of physician implementation of treatment guidelines for patients at risk of CVD. 43 In addition, the simultaneous treatment of multiple risk factors, and frequent requirement for multiple antihypertensive medications to control BP alone, may lead to complex treatment regimens and an associated decrease in patient adherence to therapy. 44 Single-pill amlodipine/atorvastatin therapy could improve patient adherence to concomitant BP and lipid-lowering medications by simplifying the treatment regimen, and synchronising the initiation of CCB and statin therapy. 44, 45 In two recent retrospective studies, adherence with single-pill amlodipine/atorvastatin was approximately twice that with amlodipine and atorvastatin co-administered in a two-pill regimen over a 6-month period among patients previously taking either a CCB or a statin (but not both). 46, 47 Although the Gemini-AALA study was not designed to assess the efficacy of single-pill amlodipine/atorvastatin therapy in comparison with the separate agents, reductions in BP and lipids were similar to, or slightly greater than, those observed in studies of co-administered amlodipine and atorvastatin. 23, 28 Therefore, in routine clinical practice, the single pill could provide greater levels of goal attainment than the separate therapies through increased medication adherence. 46, 47 Recent guidelines recommend that therapeutic strategies for CVD management take into account the effect of multiple risk factors on a patient's overall CV risk. [11] [12] [13] [14] Currently, physicians are likely to treat CV risk factors individually. However, treatment of large elevations in a single risk factor may leave the patient with a residual risk of CVD because of the presence of moderate elevations in additional risk factors. By applying a combination of treatment strategies targeting multiple risk factors, we begin to address the residual risk left by single factor treatment.
Importantly, we demonstrated that among patients in the Gemini-AALA study who did not already have CHD or a risk equivalent, predicted Framingham 10-year risk of CHD was reduced by approximately half following treatment with amlodipine/ atorvastatin. Framingham calculations have been used in previous trials to assess efficacy 28, 48 and have been adopted by treatment guidelines, including NCEP ATP III, to determine patient risk levels. 11 However, it should be noted that there are several known limitations of Framingham 10-year CHD risk estimations, such as family history of CHD is not incorporated in the model, short-term reductions in risk factors will not necessarily eliminate associated accumulated risks and Framingham estimations are not designed or validated for evaluating treatment benefits. In particular, risk scores may not apply equally to all populations or the diverse ethnic groups in this study. 49 To obtain a more accurate assessment of an individual's risk, it may be preferable to use regional or country-specific risk scores (where available); however, for the purposes of this study, the use of this single, uncomplicated risk calculation allowed a direct comparison of the changes in patients' estimated risk due to BP and lipid reductions across the overall population. In addition, although the accuracy of Framingham calculations to predict absolute risk may vary in different populations, relative changes in risk as a result of risk factor modification may be more comparable.
The estimated reductions in predicted CHD risk mediated by BP and cholesterol-lowering with amlodipine/atorvastatin in the Gemini-AALA study are also supported by clinical trials data, which have demonstrated that BP and lipid-lowering therapies reduce the incidence of CV events. 9, 19, 20, [50] [51] [52] [53] In particular, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA), 54 atorvastatin added to an amlodipine-or atenololbased antihypertensive regimen reduced the incidence of non-fatal myocardial infarction or mortality due to CHD by 53% (Po0.0001) and 16% (P ¼ NS), respectively, versus placebo, in hypertensive patients with multiple CV risk factors (total cholesterol p6.5 mmol l À1 (p250 mgdl À1 )). 54, 55 Although the open-label, non-comparative design of the Gemini-AALA study should be recognized as a potential limitation, we felt that this represented a 'real-world' approach to simulate the clinical practice setting, and allowed a more realistic assessment of the clinical utility of this therapy in a variety of patients with different treatment backgrounds and of diverse ethnicities. Furthermore, the efficacy and safety profile of single-pill amlodipine/atorvastatin therapy were comparable with that observed in previous placebo-controlled studies of co-administered amlodipine and atorvastatin or the individual drugs. 17, 18, [23] [24] [25] 27, 28, 33, 50 Overall, a higher incidence of AEs, and in particular peripheral oedema, was reported for Latin America than for the other regions in the study. We are unable to determine from the study data whether this is related to ethnic differences between the study populations, or if this is a result of regional differences in diagnosis or AE reporting. However, this potential effect should be evaluated further in future research. The relatively short trial duration, which precluded an analysis of CV outcomes, is an additional limitation of this study. Longer-term studies should be conducted to evaluate whether the observed increases in goal attainment, and decreases in predicted CHD risk, are translated into reductions in CV events.
The results of the Gemini-AALA study demonstrate that a combination tablet of amlodipine/ atorvastatin is an effective treatment with broad clinical utility in a real-world, multinational setting to help patients from diverse ethnic backgrounds with concomitant hypertension and dyslipidaemia achieve recommended BP and lipid targets, and reduce their overall CHD risk.
